Evidence map›Paper›PMID 36686400›Full record

ArticleVaccine: X2023

Achieving immunization agenda 2030 coverage targets for 14 pathogens: Projected product and immunization delivery costs for 194 Countries, 2021-2030.

Salin Sriudomporn, Elizabeth Watts, So Yoon Sim, Raymond Hutubessy, Bryan Patenaude

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine: X, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. [Price effects of global vaccine pooled procurement].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Salin SriudompornInternational Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Elizabeth WattsDivision of Health Policy and Management, University of Minnesota School of Public Health, Minneapolis, Minnesota, USA.
So Yoon SimImmunization Analysis & Insights (IAI) unit, Department of Immunization, Vaccines and Biologicals (IVB), World Health Organization, Geneva, Switzerland.
Raymond HutubessyImmunization Analysis & Insights (IAI) unit, Department of Immunization, Vaccines and Biologicals (IVB), World Health Organization, Geneva, Switzerland.
Bryan PatenaudeInternational Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Funding

World Health Organization 001
6 · The paper itself

Abstract

Understanding the level of investment needed for the next decade is vital to achieve the goal of Immunization Agenda 2030 (IA2030). Through the immunization funder perspective, this study estimates both global and regional economic resources required to achieve IA2030 coverage among 194 WHO member countries from 2021 to 2030, against 14 pathogens: Hepatitis B (Hep B),

Indexed as

CostEconomicsImmunisationInvestmentVaccine

Identifiers

PMID36686400
PMCPMC9850055

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.